BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20200101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210323
DTEND;VALUE=DATE:20210326
DTSTAMP:20260515T163041
CREATED:20210119T095042Z
LAST-MODIFIED:20210119T095042Z
UID:28574-1616457600-1616716799@www.pharmajournalist.com
SUMMARY:FcRn-Targeted Therapies for Autoimmune Disorders Summit
DESCRIPTION:The neonatal Fc receptor (FcRn) plays a fundamental role in the transcytosis\, half-life extension\, and recycling of human serum albumin and IgG\, however in the case of more than 100+ rare and autoimmune disorders\, this can not only be detrimental\, but lethal to the health of the individual. Following the high profile J&J-Momenta deal\, UCB’s rozanolixizumab expects a Ph3 readout in H1 2021 and Argenx’s efgartigimod awaits US filing by the end of 2020\, other large players are poised to bring their candidates through the clinic in rapid succession. \n \nThe digital FcRn-Targeted Therapies for Autoimmune Disorders Summit is not only the first\, but the only dedicated meeting that brings you the most up to date clinical and commercial developments utilizing FcRn antagonists in rare and autoimmune diseases. \nThe 3-day program will bring together a wealth of knowledge into the complexities of the FcRn-IgG interaction and the therapeutic strategies which are being employed to yield clinical efficacy. Expect to hear from industry leaders showcasing clinical candidates aimed at disrupting the autoantibody interaction and increasing the clearance of pathogenic IgG from the body. \nJoin 100+ experts online from companies such as CSL Behring\, Eli Lilly\, Roche\, Momenta\, Alexion\, Argenx and more to discuss FcRn MOA\, preclinical model selection and translation\, high throughput assays for ligand screening\, IgG engineering\, and DMPK modelling to ensure best in class medicines are brought to patients. Including an exclusive workshop lead by the FDA who will be exploring protein immunogenicity to better understand FcRn drug development.
URL:https://www.pharmajournalist.com/event/fcrn-targeted-therapies-for-autoimmune-disorders-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210323
DTEND;VALUE=DATE:20210325
DTSTAMP:20260515T163041
CREATED:20210226T101236Z
LAST-MODIFIED:20210226T101236Z
UID:29150-1616457600-1616630399@www.pharmajournalist.com
SUMMARY:5th Annual MarketsandMarkets High Potent Medicines Virtual Conference (CET TIME ZONE)
DESCRIPTION:One of the major challenges faced by the players in this market\, especially CMOs that offer HPAPI manufacturing services\, is the continual evolution of industry standards\, technologies\, and regulations. \nOwing to their target release characteristics\, HPAPIs find major applications in target therapies for cancer. Globally\, there is a significant growth in the incidence of cancer. Diseases like musculoskeletal diseases\, glaucoma\, and specifically cancer have a significant impact on the health status of people worldwide\, with comparatively higher growth rates in developing countries. \nThe 5th Annual MarketsandMarkets High Potent Medicines Virtual Conference to be held on 23-24 March 2021. This conference would address the challenges in continual evolution of industry standards\, technologies\, and regulations. Leading experts from the industry will discuss the strategies for both in-house manufacturing and outsourcing by presenting expert keynote presentations\, live case studies and breakthrough panel discussions. \nEvent Website https://events.marketsandmarkets.com/5th-annual-marketsandmarkets-high-potent-medicines-virtual-conference/ \nRegistration link: https://events.marketsandmarkets.com/5th-annual-marketsandmarkets-high-potent-medicines-virtual-conference/register  
URL:https://www.pharmajournalist.com/event/5th-annual-marketsandmarkets-high-potent-medicines-virtual-conference-cet-time-zone/
LOCATION:Virtual
ORGANIZER;CN="Marketsandmarkets":MAILTO:Shardul.oza@marketsandmarkets.com, events@marketsandmarkets.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210324
DTEND;VALUE=DATE:20210326
DTSTAMP:20260515T163041
CREATED:20201119T113716Z
LAST-MODIFIED:20201119T113716Z
UID:27982-1616544000-1616716799@www.pharmajournalist.com
SUMMARY:Cytokine-Based Cancer Immunotherapies Summit
DESCRIPTION:Pioneering Research to Develop Safe & Effective Immunomodulators to Stimulate the Soluble Tumor Microenvironment \nThe renewed interest in the anti-tumor properties of cytokines has led to an increase in the number of clinical trials that explore the safety and efficacy of cytokine-based drugs\, not only as single agents\, but also in combination with other immunomodulatory drugs. \n \nTherapeutically targeting of soluble immune modulators in the tumor microenvironment (TME) has been shown to create a ‘hot’ tumor\, increasing T cell infiltration and improving response rates to immune checkpoint blockade treatment. The immuno-oncology research community is pivoting towards engineering soluble factors and cytokines to transform the TME into an immunostimulatory state\, acting as a complementary strategy to a suite of cancer immunotherapies approaches. \nThe virtual Cytokine-Based Cancer Immunotherapies Summit has been established to give drug developers insight into the latest clinical advancements and stimulate discussions around how to take immuno-oncology combinations forward to meet the vast unmet need of cancer patients. \nJoin us and leading experts from Roche\, CytomX\, Philogen\, Bristol-Myers Squibb\, Novartis and many more to discuss how to reduce toxicity and achieve an efficacious dose\, determining the mechanisms of action and hear the latest data coming out of the clinic. \nTo know more about Cytokine-Based Cancer Immunotherapies Summit please click here.
URL:https://www.pharmajournalist.com/event/cytokine-based-cancer-immunotherapies-summit/
LOCATION:Digital Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210324
DTEND;VALUE=DATE:20210326
DTSTAMP:20260515T163041
CREATED:20210114T091620Z
LAST-MODIFIED:20210122T141247Z
UID:28478-1616544000-1616716799@www.pharmajournalist.com
SUMMARY:Animal Microbiome Congress
DESCRIPTION:The 4th Annual Animal Microbiome Congress taking place on the 24-25th March 2021 will provide the latest clinical data and facilitate interactions between academia and industry to accelerate the commercialization of animal microbiome research. This global market is forecast to grow to 9.7 billion by 2028 due to demand for innovation from the rapidly growing meat\, aquaculture\, and pet healthcare industries to meet an increasing need to replace antibiotics and satisfy the world’s growing hunger for protein. Over 4 years and 7 events\, we have built an international animal microbiome community of 600+ people from 30+ countries. \n \nThrough comprehensive industry-academic discussion panels\, engaging keynotes\, interactive roundtables\, and virtual networking this congress will enable participants to be at the forefront of modulating the animal microbiome to meet commercial goals\, sustainably and safely. Our goal is to support smart interactions between business and academia to enable participants to capitalize on the growing global animal microbiome market. Due to this year’s virtual format\, we have advanced our networking capabilities to help you recreate the unexpected interactions that drive the future of your work. We have incorporated: network roulette enabling 30 + chance encounters\, Deep Dive Roundtable groups of 9 people working together to tackle industry issues\, interactive content delivery to facilitate discussion and pre-arranged meetings to broaden your network strategically. \nJoin us and discover the critical breakthroughs on: uncovering the full functional potential of the microbiome in aquaculture\, production\, and companion animals\, improving health outcomes for production and companion animals\, reducing the cost of animal ownership and making farming more sustainable\, and translating academic research into commercial products whilst steering through challenging regulatory hurdles. \nBook now to join us in unlocking the full functional potential of the Animal Microbiome.
URL:https://www.pharmajournalist.com/event/animal-microbiome/
LOCATION:Virtual
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20210324
DTEND;VALUE=DATE:20210327
DTSTAMP:20260515T163041
CREATED:20210226T115030Z
LAST-MODIFIED:20210226T115030Z
UID:29181-1616544000-1616803199@www.pharmajournalist.com
SUMMARY:8th Edition MarketsandMarkets Biomarker and Companion Diagnostics Virtual Conference ( Time Zone - CENTRAL EUROPEAN TIME (CET)
DESCRIPTION:The 8th Edition Biomarker and Companion Diagnostics Virtual Conference scheduled to be held on 25 – 26 March 2021 would address the gaps between early stage biomarker development and the commercialization stage of biomarkers. This conference would also highlight case studies on leveraging emerging technologies in Digital Biomarkers\, Precision Medicine and Big Data. \nRegarding commercialization of biomarkers\, leading industry and academic experts would share their case studies focusing on advancements in companion diagnostics area. The keynote presentations would also help the attendees understand the issues related to clinical translation of biomarkers. \nEvent Website https://events.marketsandmarkets.com/8th-edition-marketsandmarkets-biomarker-and-companion-diagnostics-virtual-conference/ \nRegistration link: https://events.marketsandmarkets.com/8th-edition-marketsandmarkets-biomarker-and-companion-diagnostics-virtual-conference/register
URL:https://www.pharmajournalist.com/event/8th-edition-marketsandmarkets-biomarker-and-companion-diagnostics-virtual-conference-time-zone-central-european-time-cet/
LOCATION:Virtual
ORGANIZER;CN="Marketsandmarkets":MAILTO:Shardul.oza@marketsandmarkets.com, events@marketsandmarkets.com
END:VEVENT
END:VCALENDAR